Organigram Global (OGI) Liabilities from Discontinued Operations (2018)
Organigram Global (OGI) posted quarterly Liabilities from Discontinued Operations of 49644.39 for Q3 2018.
Organigram Global (OGI) Liabilities from Discontinued Operations (2018) Analysis & Trends
Organigram Global (OGI) has reported Liabilities from Discontinued Operations for 1 consecutive years, with 49644.39 the latest figure, recorded in Q3 2018.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 49644.39 in Q3 2018, while the trailing twelve-month figure through Aug 2018 was 49644.39 (changed N/A YoY) and the FY2018 annual result came in at 50917.42, changed N/A from the prior year.
- Liabilities from Discontinued Operations was little changed at 49644.39 in Q3 2018 per OGI's latest filing.
- Over the last five years, Liabilities from Discontinued Operations for OGI reached as high as 49644.39 in Q3 2018 and fell as low as 49644.39 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Organigram Global | 89.89 Mn | 122.96 Mn | 28.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2018 | 49,644.39 |
| Aug 31, 2018 | 49,644.39 |